Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...

June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal ...

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. The deal, ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

A Shanghai-based biopharmaceutical company commercializing rare kidney and autoimmune treatments across Greater China and ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data.

Obinutuzumab tops immunosuppressant tacrolimus for membranous nephropathy remissions ...